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Abstract: Special AT-rich sequence binding protein-2 (SATB2) is selectively expressed in the lower gastrointestinal 
tract mucosa and has been identified as a sensitive marker for colorectal adenocarcinomas. The goal of this study 
was to investigate the expression of SATB2 in well-differentiated neuroendocrine tumors to explore its potential 
as a diagnostic marker for hindgut well-differentiated neuroendocrine tumors. Immunohistochemical staining with 
a monoclonal antibody to SATB2 was performed on full tissue blocks in 167 well-differentiated neuroendocrine 
tumors of various origins. The staining was semi-quantitatively scored as 0 (no tumor cell staining), 1+ (1-25%), 
2+ (26-50%), 3+ (51-75%) and 4+ (76-100%). Positive SATB2 staining was seen in 17% foregut (14/84, 12/66 
primary and 2/18 metastatic), 12% midgut (3/22, 3/18 primary and 0/7 metastatic), and 90% hindgut (52/58, 
44/49 primary and 8/9 metastatic) well differentiated neuroendocrine tumors. Most hindgut well-differentiated 
neuroendocrine tumors (41/58) showed 4+ staining. The specificity of SATB2 for foregut, midgut and hindgut well-
differentiated neuroendocrine tumors was 34%, 54% and 84%, respectively. Our results indicate that SATB2 is a 
sensitive marker for hindgut well-differentiated neuroendocrine tumors though it is not entirely specific. SATB2 
should be included in the immunohistochemical panel in working out metastatic well-differentiated neuroendocrine 
tumor of an unknown origin. 
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Introduction
The incidence of neuroendocrine neoplasms 
has increased dramatically during the past 30 
years [1]. Neuroendocrine neoplasms are divid-
ed into well-differentiated neuroendocrine 
tumors (WDNETs) and poorly differentiated 
neuroendocrine carcinomas (PDNECs). PDNECs 
are highly aggressive and treated similarly with 
platinum-based chemotherapy regardless of 
their origin, whereas WDNETs exhibit a wide 
range of biological behavior and are treated dif-
ferently according to their primary sites [2]. 
Most WDNETs present with locoregional dis-
ease but as many as 20% of them present with 
distant metastasis [1]. This number is even 
higher for WDNETs from certain organs such as 
pancreas and ileojejunum [1]. Even though non-
surgical approaches (chemotherapy and/or 
radiation) are the main treatment for metastat-
ic WDNETs, surgical resection of both primary 
and metastatic tumors are still beneficial in 
some of these patients because cytoreduction 
can reduce acute complication in primary site, 
minimize endocrine symptoms and decrease 
the requirement of somatostatin analogs [3, 4]. 
In addition, chemotherapy and targeted therapy 
protocols are different for metastatic well dif-
ferentiated neuroendocrine tumors of different 
origins [2, 5]. Therefore determination of the 
primary origins of metastatic WDNETs has 
some therapeutic implications. 
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Recently, special AT-rich se- 
quence binding protein-2 
(SATB2) has been identified 
as a marker with a highly 
selective expression pattern 
in the lower gastrointestinal 
tract mucosa [11]. About 85- 
93% colorectal adenocarci-
nomas were immunohisto-
chemically positive for SA- 
TB2 [11, 12]. During our clin-
ical practice, we have ob- 
served that SATB2 labels all 
epithelial cells in lower gas-
trointestinal mucosa, implic- 
ating that SATB2 labels bo- 
th non-neuroendocrine epi-
thelial cells and neuroendo-
crine cells. Mucosal neuro-
endocrine cells give rise to 
neuroendocrine tumors. In 
this study, with immunohis-
tochemical staining we in- 
vestigated SATB2 expres-
Table 1. Immunohistochemical staining result of SATB2 in 84 fore-
gut well differentiated neuroendocrine tumors
Site of Origin Primary Metastatic Total
Stomach (N = 22) 2/19 (10%) 0/3 (0%) 2/22 (9%)
Duodenal (proximal half) (N = 13) 1/12 (8%) 0/1 (0%) 1/13 (8%)
Pancreas (N = 27) 2/13 (15%) 2/14 (14%) 4/27 (15%)
Gallbladder (N = 1) 0/1 (0%) 0/0 0/1 (0%)
Lung (N = 13) 3/13 (23%) 0/0 3/13 (23%)
Thymus (N = 8) 4/8 (50%) 0/0 4/8 (50%)
Total (N = 84) 12/66 (18%) 2/18 (11%) 14/84 (17%)
Determination of the origin of metastatic 
WDNETs is usually achieved with imaging stud-
ies including CT and somatostatic receptor 
imaging (Octroscan). However, these traditional 
imaging techniques had a less than 50% suc-
cessful rate in determining the primary site of 
metastatic WDNETs of unknown origin [6-8]. 
Approximately 9-19% of WDNETs still present 
with unknown origins and such tumors account 
for approximately 5% of malignancies of 
unknown origin [2, 9, 10]. Expensive PET/CT 
tracer may be more sensitive but it is not avail-
able in many areas. Therefore, in some instanc-
es determination of the origin of metastatic 
WDNETs still rely on pathology. However, 
WDNETs from different sites have similar and 
overlapping morphology, and it is often difficult 
to determine their origin just based on morphol-
ogy. In these situations, immunohistochemical 
markers are often needed to facilitate to deter-
mine the primary site of a metastatic WDNET. 
Case selection 
The study was approved by the Institutional 
Ethnic Committees (Institutional Review 
Boards). The surgical pathology files of Peking 
University Cancer Hospital, the Chinese PLA 
General Hospital, the Second Affiliated Hospital 
of Guangzhou Medical College, Hubei Cancer 
Hospital, and the second Affiliated Hospital of 
Jilin University were searched for WDNETs/car-
cinoids. The diagnosis of all WDNETs was con-
firmed with immunohistochemical staining of 
chromogranin and synaptophysin. Ki-67 prolif-
eration index was also performed for all gastro-
intestinal and pancreatic neuroendocrine neo-
plasms for grading purpose. The grades of gas-
trointestinal and pancreatic neuroendocrine 
neoplasms were assigned according to the 
WHO 2010 criteria (G1: mitotic count < 2 per 
10 high power fields (HPFs) and/or ≤ 2% Ki-67 
index; G2: mitotic count 2-20 per 10 HPFs and/
or 3-20% Ki67 index; G3 mitotic count > 20 per 
Table 2. Immunohistochemical staining result of SATB2 in 25 midgut 
well differentiated neuroendocrine tumors
Site of Origin Primary Metastatic Total 
Ileum (N = 13) 1/8 (13%) 0/5 1/13 (8%)
Jejunum (N = 3) 0/2 0/1 0/3
Appendix (N = 4) 1/4 (25%) 0/0 1/4 (25%)
Cecum and ascending colon (N = 5) 1/4 0/1 1/5 (20%)
Total (N = 25) 3/18 (17%) 0/7 (0%) 3/25 (12%)
Table 3. Immunohistochemical staining result of SATB2 
in 58 hindgut well differentiated neuroendocrine tumors
Site of Origin Primary Metastatic Total
Sigmoid colon (N = 1) 1/1 (100%) 0/0 1/1 (100%)
Rectum (N = 57) 43/48 (90%) 8/9 (89%) 51/57 (89%) 
Total (N = 58) 44/49 (90%) 8/9 (89%) 52/58 (90%) 
sion in 167 well-differentiated neuroen-
docrine tumors from various sites to 
explore the possible utility of SATB2 as 
a diagnostic marker for lower gastroin-
testinal WDNETs especially in the meta-
static setting. 
Materials and methods
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Table 4. Comparison of SATB2 staining in foregut, midgut, and hindgut well differentiated neuroendo-
crine tumors 
Site of Origin Percentage of tumors positive for SATB2 staining P value 
Foregut (N = 84) 17% (14/84) P < 0.001 between foregut and hindgut
Midgut (N = 25) 12% (3/25 ) P < 0.001 between midgut and hindgut
Hindgut (N = 58) 90% (52/58) P = 0.76 between foregut and midgut
10 HPFs and/or > 20% Ki67 index [13]. G1 and 
G2 gastrointestinal and pancreatic neuroendo-
crine neoplasms are classified as WDNETs 
whereas G3 tumors are PDNECs. In thymus and 
lung, carcinoid and atypical carcinoid are clas-
sified as WDNETs, and small cell carcinoma 
and large cell neuroendocrine carcinoma are 
classified as PDNECs. 
One hundred sixty-seven (167) WDNETs were 
collected including 133 primary and 34 meta-
static ones (Tables 1-4). These tumors were 
assigned to foregut (N = 84), midgut (N = 25) 
and hindgut (N = 58) origins according to previ-
ous criteria [14]. The foregut WDNETs included 
those from lung (11 carcinoids, 2 atypical carci-
noids; all primary), thymus (6 carcinoids, 2 
atypical carcinoids; all primary), pancreas (13 
G1, 14 G2; 13 primary and 14 metastatic), gall-
bladder (1 G1, primary), esophagus (N = 0), 
stomach (14 G1, 8 G2; 19 primary and 3 meta-
static) and the proximal half of the duodenum 
(8 G1, 5 G2; 12 primary and 1 metastatic). 
WDNETs from the distal half of duodenum (N = 
0), jejunum (2 G1, 1 G2; 2 primary and 1 meta-
static), ileum (11 G1, 2 G2; 8 primary and 5 
metastatic), cecum (1 G2, primary), appendix (4 
G1, all primary), ascending colon (3 G1, 1 G2; 3 
primary and 1 metastatic), and proximal 1/3 
transverse colon (N = 0) are classified as mid-
gut WDNETs. Hindgut WDNETs are those from 
distal 2/3 transverse colon (N = 0), descending 
colon (N = 0), sigmoid colon (1 G1, primary) and 
rectum (45 G1, 12 G2; primary 48, metastatic 
9). 
TB2 (clone EPNCIR130A, dilution 1:100, Ori- 
Gene Technologies, Maryland, USA). Appro- 
priate positive and negative controls were 
included for each batch of immunohistochemi-
cal staining. Only nuclear staining was consid-
ered positive. The immunohistochemical stain-
ing was scored semi-quantitatively as 0 (no 
tumor cell staining), 1+ (1-25% tumor cells 
stained), 2+ (26-50%), 3+ (51-75%), and 4+ 
(76-100%). 
Statistic analysis
Fisher exact test was used to compare the 
SATB2 staining among foregut, midgut and 
hindgut WDNETs. A P value < 0.05 was consid-
ered statistically significant. The sensitivity, 
specificity, positive predictive value (PPV) and 
negative predictive value (NPV) were calculated 
with the following formats: sensitivity = number 
of true positives/(number of true positives + 
number of false negatives), specificity = num-
ber of true negatives/(number of true negatives 
and number of false positives), PPV = number 
of true positives/(number of true positives + 
number of false positives), and NPV = number 
of true negatives/(number of true negatives 
and number of false negatives). 
Results
SATB2 staining in foregut well differentiated 
neuroendocrine tumors (N = 84)
Among the 84 foregut WDNETs, 14 (17%) 
showed positive SATB2 staining including 
12/66 (18%) primary and 2/18 (11%) metastat-
Table 5. Sensitivity, specificity, positive predictive value and negative pre-
dictive value of SATB2 for 167 well differentiated neuroendocrine tumors
Foregut WDNETs Midgut WDNETs Hindgut WDNETs
Sensitivity 17% (14/84) 12% (3/25) 90% (52/58)
Specificity 34% (28/83) 54% (76/142) 84% (92/109)
Positive predictive value 20% (14/69) 4% (3/69) 75% (51/69)
Negative predictive value 29% (28/98) 78% (76/98) 94% (92/98)
Immunohistochemistry
One formalin fixed par-
affin embedded tissue 
block from each case 
was used to generate 4 
um unstained slides for 
immunohistochemical 
staining with a mono-
clonal antibody to SA- 
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Figure 1. In this study 90% of rectal well differentiated neuroendocrine tumors (A, B) showed positive staining for 
SATB2 with most of them showing diffuse staining (C). The normal rectal mucosal epithelium showed diffuse SATB2 
staining (C). This tumor was negative for CDX2 (D). Normal rectal mucosal epithelium was positive for CDX2.
ic tumors (Table 1). Primary tumors and meta-
static ones did not show difference in SATB2 
staining (P = 0.7238). 
Among the 12 (of 66) primary tumors showing 
positive SATB2 staining, 8 showed staining in 
no more than 50% tumor cells (1+ in 6/12, 2+ 
in 2/12) and 4 showed staining in more than 
50% tumor cells (3+ in 2/12, 4+ in 2/12). The 
two metastatic tumors (both from pancreas) 
showed 2+ and 3+ staining, respectively. 
SATB2 staining in midgut well differentiated 
neuroendocrine tumors (N = 25)
Positive SATB2 staining was seen in 3/25 (12%) 
midgut WDNETs including 3/18 (17%) primary 
and 0/7 (0%) metastatic ones (Table 2). The 
percentage of tumor cells showing SATB2 stain-
ing was no more than 50% in all 3 cases (1+ in 
1, 2+ in 2). 
SATB2 staining in hindgut well differentiated 
neuroendocrine tumors (N = 58)
Among the 58 hindgut WDNETs, positive SATB2 
staining was seen in 52 (89%) tumors including 
44/49 (90%) primary (Figure 1) and 8/9 (89%) 
metastatic tumors (Figure 2; Table 3). The 
staining pattern distribution in 44 SATB2-
positive primary tumors was 1+ in 4 (4/44, 9%), 
2+ in 4 (4/44, 9%), 3+ in 2 (2/44, 5%), 4+ in 34 
(34/44, 77%). Among the 8 (of 9) SATB2-
positive metastatic hindgut WDNETs, 7 (88%) 
showed 4+ staining and 1 (12%) showed 3+ 
staining. Overall 41 of 58 (71%) hindgut 
WDNETs showed 4+ staining. 
Sensitivity and specificity of SATB2 for well-
differentiated neuroendocrine tumors from 
foregut, midgut and hindgut 
In this study, the sensitivity of SATB2 for label-
ing foregut, midgut and hindgut WDNETs was 
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Figure 2. This rectal well differentiated neuroendocrine tumor that metastasized to the liver (A1) was positive for 
SATB2 (B1) but negative for CDX2 (C1). In contrast, an ileal well differentiated neuroendocrine tumor that metasta-
sized to one ovary (A2) showed negative staining for SATB2 (B2) but was positive for CDX2 (C2).
17%, 12% and 90%, respectively (P < 0.001 
between foregut and hindgut, P < 0.001 
between midgut and hindgut, P = 0.76 between 
foregut and midgut) (Table 4). The specificity of 
SATB2 for foregut, midgut and hindgut WDNETs 
was 34%, 54% and 84%, respectively (Table 5). 
The positive predictive value of SATB2 for fore-
gut, midgut and hindgut WDNETs was 20%, 4%, 
and 75%, respectively (Table 5). The negative 
predictive value of SATB2 for foregut, midgut 
and hindgut WDNETs was 29%, 78%, and 94%, 
respectively (Table 5).
Discussion 
SATB2 is a DNA-binding protein that interacts 
with transcription factors to regulate craniofac-
tial development, cortical neuron differentia-
Diagnostic markers for well differentiated neuroendocrine tumors
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tion, immunoglobulin mu gene expression, skel-
etal development and osteoblastic differentia-
tion [15-18]. In a previous study [11], 
Magnusson et al first showed that SATB2 was a 
sensitive marker (85% sensitivity) for colorectal 
adenocarcinomas, which was later confirmed 
by another study (93% sensitivity) [12]. In addi-
tion, SATB2 was also a sensitive osteoblastic 
marker [19, 20]. 
In this study, we investigated the expression of 
SATB2 in a large series of 167 WDNETs. We 
found that SATB2 staining was seen in 17% 
foregut, 12% midgut and 90% hindgut WDNETs. 
Among those 52 (of 58) SATB2-positive hindgut 
WDNETs, most of them (44/52 or 85%) showed 
staining in more than 50% tumor cells and 80% 
(41/52) labeled more than 90% tumor cells (4 
+ staining). Our study indicates that among 
WDNETs, SATB2 is preferentially expressed in 
hindgut WDNETs and is therefore a sensitive 
marker for hindgut WDNETs. The high sensitivi-
ty of SATB2 for hindgut WDNETs holds not only 
for primary tumors (44/49 or 90%) but also for 
metastatic ones (8/9 or 89%). 
Previous studies have identified several immu-
nohistochemical markers for determining the 
origins of metastatic WDNETs. These markers 
included thyroid transcription factor 1 (TTF1), 
caudal type homeobox 2 (CDX2), neuroendo-
crine secretory protein-55 (NESP-55),  (PDX1), 
paired box 8 (PAX8), and Islet1 [2, 21-48]. TTF1 
is a relatively specific marker for pulmonary car-
cinoid/atypical carcinoids (the overall sensitivi-
ty is 32%) [2, 21, 22, 24, 25, 31, 32, 35]. CDX2 
is considered a sensitive marker for midgut 
WDNETs (86-92% sensitivity) but some foregut 
(3% to 33%) and hindgut (29-43%) WDNETs 
also show immunoreactivity [2, 23-32, 35, 36]. 
NESP55 is relatively specific for pancreatic 
WDNETs but with low sensitivity (50% sensitivi-
ty) [2, 31-34]. PDX1 mainly labeled gastroduo-
denopancreatic WDNETs (46-60% sensitivity) 
but it also labeled a variable percentage of lung 
(3/39 or 8%), appendiceal (7/17 or 41%) and 
rectal (2/14 or 14%) WDNETs [2, 31, 35-39]. 
PAX8 and Islet1 mainly labeled foregut (61-
68% and 80-89% duodenopancreatic WDNETs, 
respectively) and hindgut WDNETs (56% and 
88% rectal WDNETs, respectively) [2, 39-48]. 
When compared to these previously reported 
markers, SATB2 showed similar sensitivity to 
Islet1 for rectal WDNETs (89% versus 88%, P = 
1.0) and was more sensitive than PAX8 for 
these tumors (89% versus 56%, P < 0.01). The 
specificity of SATB2, Islet1 and PAX8 for rectal 
WDNETs was 84%, 55%, and 63%, respectively 
(P < 0.01 between SATB2 versus Islet1, P < 
0.01 between SATB2 and PAX8) (specificity for 
Islet1 and PAX8 was calculated based on the 
data from literature as summarized in Table 6). 
Therefore even though SATB2 and Islet1 show 
similar sensitivity for rectal WDNETs, SATB2 is 
more specific than Islet1 for these tumors. 
SATB2 is both more sensitive and specific than 
PAX8 for rectal WDNETs. Another marker for 
rectal WDNETs that is not usually used but 
reported in the early literature is prostatic acid 
phosphatase (PASP) [49-53]. The reported pos-
itive rate of PSAP in large series of rectal 
WDNETs (carcinoids) was ranging from 67-82% 
[49-53], not as sensitive as SATB2. Although 
SATB2 is not specific for hindgut WDNETs, it 
has a high negative predictive value (94%) i.e. a 
WDNET negative for SATB2 is unlikely from the 
hindgut region. 
The proportions of WDNETs arising foregut, 
midgut and hindgut origins are highly variable 
among different racial groups. In the USA SEER 
data, in Caucasians foregut WDNETs were most 
common (45%) followed by midgut (25%) and 
hindgut ones (12-16%) whereas in Asians/
Pacific islanders, the most common WDNETs 
were from hindgut (approximately 41-45%, 
more than 90% hindgut WDNETs were rectal) 
followed by foregut (34%) and midgut (7%) [1]. 
In east Asian countries such as China, Korea 
and Japan, hindgut WDNETs (vast majority are 
rectal) account for 50-70% of gastrointestinal 
WDNETs and only 10% of gastrointestinal 
WDNETs are of midgut origin [54, 59]. The dis-
tant metastasis rate of rectal WDNETs is relat-
ed to the tumor size, ranging from 5.5% in less 
than 1.0 cm tumors to 4-30% in 1.0-1.9 cm 
tumors to 70-80% in tumors 2.0 cm or larger 
[54-59]. Given the large number of population 
in East Asian countries, the number of patients 
with metastatic rectal WDNETs is not small [54-
59]. Even in USA, in a recent study 13% (11/85) 
rectal WDNETs were metastatic at presentation 
and additional 5% (4/85) had metastasis on 
follow-up [60]. Therefore even though rectal 
WDNETs have a lower metastasis rate than that 
of midgut and pancreatic WDNETs, the number 
of metastatic rectal WDNETs is actually not that 
small. Most metastasis occurred in the liver but 
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Table 6. Comparison of SATB2 to other well differentiated neuroendocrine tumor markers in the literature
Markers
Foregut Origin Midgut origin Hindgut Origin
References 
Lung Stomach Pancreas Duodenum Jejunoilecum Appendix Cecum Colon Rectum 
TTF1 32% (189/588) 0.03% (4/928) [2, 21-22, 24-25, 31-32, 35]
CDX2 3% (8/233) 15% (12/80) 16% (81/499) 33% (17/52) 90% (306/339) 92% (72/78) 86% (6/7) 43% (10/23) 29% (32/112) [2, 23-32, 35-36]
NESP55 10% (2/20) 0% (0/9) 50% (49/99) 0% (0/5)  0% (0/57) 0 (0/11) NA NA 7% (1/16) [2, 31-34]
PDX1 8% (3/39) 60% (3/5) 56% (124/220) 46% (18/39) 0% (0/49) 41% (7/17) 0% (0/3) 0% (0/2) 14% (2/14) [2, 35-39]
PAX8 6% (7/117) 14% (5/37) 68% (145/213) 61% (11/18) 0% (0/152) 17% (5/30) NA 0% (0/1) 56% (28/50) [2, 42, 44-48]
Islet1 11% (11/101) 0% (0/22) 80% (256/322) 89% (25/28) 1% (2/137) 15% (7/46) 0% (0/1) 23% (3/13) 88% (22/25) [2, 39-43]
SATB2 23% (3/13) 9% (2/22) 15% (4/27) 8% (1/13) 6% (1/16) 25% (1/4) 0% (0/1) 40% (2/5: ascending 1/4,  
sigmoid 1/1)
89% (51/57) This study 
Diagnostic markers for well differentiated neuroendocrine tumors
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rectal WDNETs can metastasize to lung and 
pancreas, creating significant difficulty in differ-
entiating them from primary pulmonary and 
pancreatic WDNETs [54-60]. In such situations, 
use of immunohistochemical markers is critical 
to make such distinction. Sensitive hindgut 
WDNET markers such as SATB2 are particularly 
useful in this aspect. Such diagnostic utility is 
even more appreciated in eastern Asian coun-
tries given the large patient population and 
high proportion of rectal WDNETs. 
It should be pointed out that even though 
SATB2 is a sensitive marker for hindgut 
WDNETs, it is not specific. As a matter of fact, 
except TTF1 (TTF1 is relatively specific for pul-
monary WDNETs and thyroidal medullary carci-
noma), none of the currently used WDNET 
markers is specific for WDNET from any particu-
lar site. Therefore a panel of immunohisto-
chemical markers is often needed in determin-
ing the primary site of a metastatic WDNET. 
Bellizzi [2] recommended an initial panel to 
include TTF1, CDX2 and PAX8 (or Islet1). We 
would recommend to add SATB2 to this panel 
to increase sensitivity and specificity for work-
ing out metastatic WDNETs of unknown origin.
Obviously SATB2 should be always used in con-
junction with tumor morphology. SATB2 was 
highly expressed in colorectal adenocarcino-
mas and occasionally in some other types of 
carcinomas [11, 12]. Therefore SATB2 is not 
useful to distinguish WDNET from adenocarci-
noma in the hindgut region. Their distinction 
relies on other parameters (morphology, mitotic 
figures/Ki67 index, and neuroendocrine mark-
ers chromogranin and synaptophysin). In addi-
tion, we have found that SATB2 is also 
expressed in approximately one third of PDNECs 
of various organs (data not published). 
Therefore SATB2 is not useful to distinguish 
WDNETs from PDNECs. 
One limitation of our study is that the number of 
metastatic WDNETs is relatively small (foregut 
18, midgut 7 and hindgut 9). Further studies 
are needed to include more WDNETs from vari-
ous sites particularly metastatic ones to test 
whether the high sensitivity of SATB2 for meta-
static hindgut WDNETs can be maintained.
In summary, we investigated SATB2 expression 
in a large series of WDNETs. Our results indi-
cate that SATB2 is a sensitive marker for hind-
gut WDNETs though it is not specific. SATB2 
should be included in the immunohistochemi-
cal panel for working out metastatic WDNETs 
from an unknown origin.
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